23.03.2023 BB BIOTECH AG  CH0038389992

EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share


 

EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share

23.03.2023 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Media release of March 23, 2023

Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share

All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 2.85 gross per share. Payment will be made on March 29, 2023, the record date is March 28, 2023 and the ex-dividend date is March 27, 2023.

Shareholders re-elected the previous board members Dr. Erich Hunziker (Chairman), Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen and Dr. Thomas von Planta for another one-year term of office.

 

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, [email protected]
Maria-Grazia Alderuccio, [email protected]
Claude Mikkelsen, [email protected]

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, [email protected]

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, [email protected]

 

www.bbbiotech.com

 

Company profile  
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.



23.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1590477

 
End of News EQS News Service

1590477  23.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1590477&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 624,17 5,13 669,48 683,90 0,00 1,28 0,57
EBITDA1,2 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBITDA-Marge3 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69
EBIT1,4 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBIT-Marge5 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69 -38.998,25
Jahresüberschuss1 587,80 -418,27 622,84 637,24 -390,53 -362,83 -222,41
Netto-Marge6 94,17 -8.153,41 93,03 93,18 0,00 -28.346,09 -39.019,30
Cashflow1,7 225,26 95,66 197,69 241,97 -91,44 234,37 234,97
Ergebnis je Aktie8 10,62 -7,55 11,24 11,51 -7,05 -6,59 -4,05
Dividende8 2,85 2,68 3,20 3,32 3,67 2,88 2,58
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 45,250 Kaufen 2.506,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,32 5,42 5,89 114,27
KBV KCV KUV EV/EBITDA
1,05 10,67 4.397,98 -11,28
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
2,88 2,10 4,64 19.03.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 26.07.2024 25.10.2024 21.02.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,22% 3,54% -0,98% -6,70%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei EQS abrufen


Biotechnologie , A0NFN3 , BBZA , XETR:BBZA